TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06672302: A Prospective Study to Develop and Clinically Validate an in Vitro Diagnostic Medical Device That Uses Blood to Classify Patients at High Risk for Breast Cancer

Sponsor: EXoPERT · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 330 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT06672302 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06672302 Rescue Dossier →